MetaCap

Ginkgo Bioworks (DNA) vs Tectonic Therapeutic (TECX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tectonic Therapeutic (TECX) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 8.1% versus a loss of 8.7%. Over five years, TECX leads with a -57.7% price change compared with -98.5% for DNA. Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $405.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNA-8.69%TECX+8.08%
+104%+32%-39%
Nov 21, 20251 yearNov 20, 2026
DNA-98.61%TECX-59.45%
+11%-47%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNA versus TECX key metrics
MetricDNATECX
Share price$7.46$20.73
Market cap$483.54M$405.26M
1-day change-9.02%-1.47%
YTD return-10.23%-0.62%
1-year return-8.69%+8.08%
5-year return-98.45%-57.66%
EPS (TTM)$-4.24$-4.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.16M—
Revenue growth (YoY)-25.06%—
Net income (latest FY)$-312.76M$-74.15M
Operating margin-185.29%—
Net margin-183.81%—
52-week high$18.22$39.53
52-week low$5.37$16.77
Distance from 52-week high-59.06%-47.56%
Analyst consensusunderperformstrong_buy
Avg. price target upside+7.24%+242.50%
Average volume2.53M212.16K
Shares outstanding53.94M19.55M
Employees48560
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TECX has outperformed DNA by 16.8 percentage points over the past year.

About Ginkgo Bioworks

DNA stock →

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees

About Tectonic Therapeutic

TECX stock →

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

DNA vs TECX FAQ

Which is bigger, Ginkgo Bioworks or Tectonic Therapeutic?

Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $405.26M for Tectonic Therapeutic (TECX).

Which stock has performed better over the past year, DNA or TECX?

TECX returned +8.08% over the past 12 months, compared with -8.69% for DNA (price return, excluding dividends). Past performance does not predict future results.

Are Ginkgo Bioworks and Tectonic Therapeutic in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons